Due to its propensity to cause outbreaks and its antifungal resistance, C. auris poses a risk for patients in healthcare facilities in Europe. Difficulties with laboratory identification, combined with a lack of awareness of this new Candida species, might result in unnoticed outbreaks. There is a clear need to raise awareness in European healthcare facilities in order adapt laboratory testing strategies and implement enhanced control measures to prevent further hospital outbreaks.
In view of new evidence, ECDC has updated its rapid risk assessment on the potential risk of invasive cardiovascular infection by M. chimaera associated with the use of heater-cooler units.
ECDC conducted a systematic review of the literature published between 2005–2015, with the aim to estimate the prevalence of hepatitis B and C in the general population and specific population subgroups in the EU/EEA Member States. This review is an update of an earlier review covering the period 2000–2009.
ECDC and the European Commission's Directorate General for Health and Food Safety jointly carried out this country visit to Bulgaria from 15 to 19 October 2018. The visit was carried out following the invitation from the competent authorities to assist them in the preparation of their national strategy for tackling antimicrobial resistance (AMR) based on a 'One Health' perspective.
This rapid risk assessment provides several options to reduce the risk of CRE, e.g. treatment options, transmission prevention and measures related to the healthcare system.
Following an invitation from the Portuguese public health authorities, an ECDC team visited Lisbon to conduct a review of Portugal’s emergency preparedness systems for imported cases of viral haemorrhagic fever (Ebola).
The goal of this systematic review is to update the 2011 ECDC risk assessment. Evidence from this review will be used to develop guidance on this topic.
This systematic review seeks to identify evidence for the effectiveness of targeted infection control measures to control the spread and transmission of ESBL-E when transferring patients between healthcare settings, especially when the transfer is cross-border.